- Home
- LOCO vs ALT Comparison
LOCO vs ALT Comparison
Compare LOCO & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LOCO | ALT |
|---|---|---|
| Founded | 1980 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 411.3M | 421.5M |
| IPO Year | 2014 | 2005 |
Fundamental Metrics
Financial Performance| Metric | LOCO | ALT |
|---|---|---|
| Price | $13.81 | $2.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $14.17 | ★ $17.67 |
| AVG Volume (30 Days) | 357.3K | ★ 2.6M |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 4.65 | ★ 25.37 |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $401,701,000.00 | $41,000.00 |
| Revenue This Year | $3.60 | N/A |
| Revenue Next Year | $3.98 | N/A |
| P/E Ratio | $51.26 | ★ N/A |
| Revenue Growth | 5.68 | ★ 105.00 |
| 52 Week Low | $8.99 | $2.56 |
| 52 Week High | $15.90 | $7.73 |
Technical Indicators
Market Signals| Indicator | LOCO | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 48.96 | 37.23 |
| Support Level | $13.52 | $2.56 |
| Resistance Level | $14.38 | $3.20 |
| Average True Range (ATR) | 0.49 | 0.13 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 19.18 | 2.25 |
Price Performance
Historical ComparisonAbout LOCO El Pollo Loco Holdings Inc.
El Pollo Loco Holdings Inc operates and franchises hundreds of fast-casual chicken restaurants in the United States. It specializes in fire-grilling citrus-marinated chicken and operates in the limited service restaurant market segment. Its offerings include Mexican-inspired menu items, including burritos, tostadas, bowls, salads, and bone-in chicken meals in various portion sizes. It also offers citrus-marinated fire-grilled chicken, along with a range of salsas and dressings that allow customers to customize their meals. The company operates in one operating segment. The majority of the company's revenue is derived from company-operated restaurant revenue.
About ALT Altimmune Inc.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.